All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Cyclooxygenase-2 gene and MAGE Gene m-RNA in hepatocellular carcinoma

Author(s): Faten Zahran, Yousri Hussien, Wael El-Sawy, Amal Ghareeb, Ibrahim Mohei, Marwa Sabea

Tumor markers in the early detection of tumors are promising tools that could improve the control and treatment of tumors. While alpha-fetoprotein (AFP) is a commonly used tumor marker in the detection of hepatocellular carcinoma (HCC), its sensitivity and specificity are insufficient to detect HCC in all patient samples. This study aimed to evaluate MAGE-1 m-RNA expression in blood, to identify functional single nucleotide polymorphisms in the cyclooxygenase-2 gene promoter and to evaluate the level of serumalpha-L-fucosidase (AFU) and alpha-fetoproteinwhich evaluated in a trial to assess their possible use as a diagnostic tool for HCV infection complications like cirrhosis and HCC. This studywas carried out on the following groups: group I: 25 healthy individuals served as control, group II: 50 HCV infection patients without any complications, group III: 50 HCVinfected patients complicated with cirrhosis and group IV: 75 HCV infected patients complicated with (45 localized and 30 metastatic) HCC. MAGE-1m-RNAexpression in blood, identification of SNP inCOX-2 gene promoter, serum levels of AFU, detection of alpha-fetoprotein using an enzyme-linked immunosorbent assay (ELISA) and some routine liver function (AST, ALT, T.B, Alb and PT) were determined and the results were statistically analyzed revealing the following:MAGE-1m-RNA determination in blood by RT-PCR assay revealed 46.1 %(31 out of 75 HCC patient) were found to be positive forMAGE-1.We found -1195Aallele carriers had a higher risk of HCC with HCVinfection.As regard the obtained results of serumAFU, a significant increase was detected in HCC as compared with cirrhosis, hepatitis and healthy control groups (p <0.001). Concerning the obtained results of serumAFP, when HCC group was compared with cirrhosis, hepatitis and healthy controls, a significant increase was observed (P< 0.001), In conclusion: detection ofMAGE-1 m-RNAin blood, identification of SNP in COX-2 gene promoter and evaluation of serumAFU and AFP have different significances and might be used as markers in screening individuals at high risk ofHCC and give a red light in early detection of HCC which may be reduce its fatal incidence.


Share this